Icon (ICLR) Cost of Revenue (2009 - 2026)
Icon's (ICLR) quarterly Cost of Revenue came in at $1.6 billion in Q2 2026, up 8.82% year-over-year from $1.5 billion in Q2 2025, and up 1.81% quarter-over-quarter from $1.6 billion in Q1 2026.
Analysis
Icon (ICLR) Cost of Revenue (2009 - 2026) Analysis & Trends
Icon (ICLR) has reported Cost of Revenue for 18 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cost of Revenue rose 8.82% year-over-year to $1.6 billion in Q2 2026; TTM through Jun 2026 was $6.3 billion, a 8.45% increase from a year earlier, with the FY2025 full-year figure at $6.1 billion, up 4.44% from the prior year.
- Cost of Revenue was $1.6 billion for Q2 2026 at Icon, up from $1.6 billion in the prior quarter.
- Over five years, Cost of Revenue peaked at $1.6 billion in Q4 2025 and troughed at $1.4 billion in Q3 2022.
- A 5-year average of $1.5 billion and a median of $1.4 billion in 2023 frame the typical range for Cost of Revenue.
- Across the five-year window, Cost of Revenue soared 120.57% in 2022 and retreated 2.53% in 2025, its largest moves.
- Over 5 years, Cost of Revenue stood at $1.4 billion in 2022, then climbed by 4.45% to $1.4 billion in 2023, then fell by 0.9% to $1.4 billion in 2024, then rose by 14.18% to $1.6 billion in 2025, then declined by 2.92% to $1.6 billion in 2026.
- The last three Cost of Revenue figures came in at $1.6 billion (Q2 2026), $1.6 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 42.77 Bn | 40.69 Bn | 1.44 Bn | 2.93 Bn |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 505.69 Mn |
| 3 | Charles River Laboratories International | 13.37 Bn | 13.18 Bn | 452.07 Mn | 552.01 Mn |
| 4 | Icon | 12.49 Bn | 11.56 Bn | 479.29 Mn | 1.58 Bn |
| 5 | Fortrea Holdings | 1.58 Bn | 1.42 Bn | 139.20 Mn | 539.00 Mn |
| 6 | Evotec SE | 642.83 Mn | 216.96 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 422.55 Mn | 338.02 Mn | 18.44 Mn | 1.72 Mn |
| 8 | Champions Oncology | 69.16 Mn | 69.16 Mn | 7.03 Mn | 6.81 Mn |
| 9 | MindWalk Holdings | 59.83 Mn | 51.55 Mn | 1.82 Mn | 1.18 Mn |
| 10 | VivoSim Labs | 1.45 Mn | 1.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.58 Bn |
| Mar 31, 2026 | 1.56 Bn |
| Dec 31, 2025 | 1.63 Bn |
| Sep 30, 2025 | 1.49 Bn |
| Jun 30, 2025 | 1.46 Bn |
| Mar 31, 2025 | 1.45 Bn |
| Dec 31, 2024 | 1.43 Bn |
| Sep 30, 2024 | 1.44 Bn |
| Jun 30, 2024 | 1.49 Bn |
| Mar 31, 2024 | 1.47 Bn |
| Dec 31, 2023 | 1.44 Bn |
| Sep 30, 2023 | 1.45 Bn |
| Jun 30, 2023 | 1.43 Bn |
| Mar 31, 2023 | 1.40 Bn |
| Dec 31, 2022 | 1.38 Bn |
| Sep 30, 2022 | 1.38 Bn |
| Jun 30, 2022 | 1.39 Bn |
| Mar 31, 2022 | 1.38 Bn |
| Dec 31, 2021 | 1.36 Bn |
| Sep 30, 2021 | 1.36 Bn |